15 active trials 12 recruiting 1 Phase 3 6 disease areas 2 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.
Recruitment opened
Also in this update: Trial sites expanded: 0 → 7 locations
Betta Pharmaceuticals Co., Ltd.Phase 1/2 NCT07435038 Registry history of NCT07435038 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 8 | |
| Phase 1/2 | 3 | |
| Phase 2 | 2 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06041776 | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR… | Non-Small Cell Lung Cancer | Recruiting | 2023-09-22 |
| Phase 2 | ||||
| NCT07181499 | Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients… | NSCLC | Recruiting | 2025-09-30 |
| NCT06885840 | Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and… | Non-Small Cell Lung Cancer | Not Yet Recruiting | 2025-03-20 |
| Phase 1/2 | ||||
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations… | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-09-18 |
| NCT07448116 | Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. | Solid Advanced Tumor | Recruiting | 2026-03-04 |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced… | Solid Tumor | Recruiting | 2026-02-10 |
| Phase 1 | ||||
| NCT07809789 | Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants | DDI (Drug-Drug Interaction) | Recruiting | 2026-09-09 |
| NCT07809802 | Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment | Hepatic Impairment (HI) | Recruiting | 2026-09-09 |
| NCT07809815 | Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants. | DDI (Drug-Drug Interaction) | Recruiting | 2026-09-09 |
| NCT06641609 | A Phase I Study of CFT8919 in Patients With Advanced NSCLC | Non-Small Cell Lung Cancer With EGFR Mutation | Recruiting | 2026-09-04 |
| NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or… | Advanced Solid Tumor | Recruiting | 2025-01-27 |
| NCT05789602 | A Study of BPI-460372 in Advanced Solid Tumor Patients | Advanced Solid Tumor | Recruiting | 2025-01-27 |
| NCT03791112 | A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor | Advanced Solid Cancer | Active, Not Recruiting | 2025-01-27 |
| NCT06015568 | Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell… | Non-Small Cell Lung Cancer、EGFR Sensitive Mutation | Not Yet Recruiting | 2023-08-29 |
| Not specified | ||||
| NCT07806604 | Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk… | NSCLC (Non-small Cell Lung Cancer) | Recruiting | 2026-09-08 |
Non-Small Cell Lung Cancer (NSCLC) (9) · Lung Cancer (7) · Colorectal Cancer (2) · Head & Neck Cancer (1) · Liver Cancer (1) · Pancreatic Cancer (1)